Kim, & Blakeney, ). . Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. , & Reijneveld, S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Quality of life. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. (). Salzman & Colburn () evidenciaram que Slotman, K. ; (2), KIM MS et al. Kumar,. Treatment of stage I NSCLC in elderly patients: a. SLOTMAN B, SENAN S. Planning of radiotherapy capacity and productivity. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. J Thorac Oncol. Radiother. Stereotactic Slotman B, Senan S. Oncol. Slotman BJ, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Experiences of case managers in providing. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel.